340B Drug Pricing Program
AHA 340B Advocacy Alliance Bulletin - September 16, 2025.
The AHA commented Sept. 15 on the Centers for Medicare & Medicaid Services calendar year 2026 outpatient prospective payment system and ambulatory surgical center payment system proposed rule.
Hospitals and health systems are experiencing significant financial pressures that challenge their ability to provide 24/7 care for the patients and communities they serve. As Congress begins to focus on its end-of-the-year work, America’s hospitals and health systems respectfully request that you…
The United States Court of Appeals for the Fifth Circuit Sept. 12 affirmed a Mississippi Court’s decision to deny AbbVie’s request for a preliminary injunction against enforcement of state law protecting 340B pricing for contract pharmacy arrangements.
The AHA Sept. 8 urged the Federal Trade Commission and Antitrust Division of the Department of Justice to investigate several drug companies’ concerted efforts to impose rebate models within the 340B Drug Pricing Program, saying the actions may violate antitrust laws.
AHA 340B Advocacy Alliance for September 8, 2025.
AHA letter to the Federal Trade Commission and Department of Justice regarding anticompetitive activity by drug companies with respect to 340B “rebate models.”
340B Advocacy Alliance Bulletin for September 5, 2025.
340B Advocacy Alliance Bulletin for September 3, 2025.
Reps. Doris Matsui, D-Calif., Dusty Johnson, R-S.D., Debbie Dingell, D-Mich., and Tracey Mann, R-Kan., are circulating a “Dear Colleague” letter asking House members to sign a letter to the Department of Health and Human Services expressing concerns about the recently announced 340B Rebate Model…